Literature DB >> 35235108

Osteopontin in autoimmune disorders: current knowledge and future perspective.

Canhua Xu1, Yaohong Wu1, Ning Liu2.   

Abstract

Osteopontin (OPN) is a multifunctional cytokine and adhesion molecule, as well as an unusual regulator for both innate and adaptive immune responses. Several immune cells can produce OPN, including dendritic cells (DCs), macrophages, and T lymphocytes. OPN expression is reported to be increased in a wide range of disorders, including autoimmunity, cancer, and allergy. The overexpression of OPN in several autoimmune disorders, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), Type 1 diabetes (T1D), inflammatory bowel disease (IBD), Sjögren's, and myasthenia gravis, have been shown to be correlated with disease severity. Regarding the important regulatory roles of OPN in the immune system, this study aimed to review the role of this molecule in autoimmune disorders and to provide a complete view of the current knowledge in this field.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Autoimmunity; IBD; Lupus; Osteopontin; Rheumatoid arthritis

Mesh:

Substances:

Year:  2022        PMID: 35235108     DOI: 10.1007/s10787-022-00932-0

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   5.093


  110 in total

1.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.

Authors:  S Ashkar; G F Weber; V Panoutsakopoulou; M E Sanchirico; M Jansson; S Zawaideh; S R Rittling; D T Denhardt; M J Glimcher; H Cantor
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

2.  The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease.

Authors:  D Chabas; S E Baranzini; D Mitchell; C C Bernard; S R Rittling; D T Denhardt; R A Sobel; C Lock; M Karpuj; R Pedotti; R Heller; J R Oksenberg; L Steinman
Journal:  Science       Date:  2001-11-23       Impact factor: 47.728

3.  Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study.

Authors:  M J H Boumans; J G A Houbiers; P Verschueren; H Ishikura; R Westhovens; E Brouwer; B Rojkovich; S Kelly; M den Adel; J Isaacs; H Jacobs; J Gomez-Reino; G M Holtkamp; A Hastings; D M Gerlag; P P Tak
Journal:  Ann Rheum Dis       Date:  2011-09-14       Impact factor: 19.103

4.  Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile.

Authors:  I Barchetta; C Alessandri; L Bertoccini; F A Cimini; L Taverniti; M Di Franco; A Fraioli; M G Baroni; M G Cavallo
Journal:  Eur J Endocrinol       Date:  2015-11-17       Impact factor: 6.664

Review 5.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

6.  Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis.

Authors:  Manjit Braitch; Robert Nunan; Graham Niepel; Laura J Edwards; Cris S Constantinescu
Journal:  Arch Neurol       Date:  2008-05

Review 7.  Regulatory T cells and inhibitory cytokines in autoimmunity.

Authors:  Maria Bettini; Dario A A Vignali
Journal:  Curr Opin Immunol       Date:  2009-10-23       Impact factor: 7.486

8.  Determination of the transcriptional level of long non-coding RNA NEAT-1, downstream target microRNAs, and genes targeted by microRNAs in diabetic neuropathy patients.

Authors:  Gelayol Asadi; Fatemeh Rezaei Varmaziar; Mojgan Karimi; Misagh Rajabinejad; Sedigheh Ranjbar; Ali Gorgin Karaji; Farhad Salari; Leila Afshar Hezarkhani; Alireza Rezaiemanesh
Journal:  Immunol Lett       Date:  2021-01-27       Impact factor: 3.685

9.  High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation.

Authors:  Annalisa Chiocchetti; Manuela Indelicato; Thea Bensi; Riccardo Mesturini; Mara Giordano; Selina Sametti; Luca Castelli; Flavia Bottarel; Maria Clorinda Mazzarino; Letizia Garbarini; Francesca Giacopelli; Guido Valesini; Claudio Santoro; Irma Dianzani; Ugo Ramenghi; Umberto Dianzani
Journal:  Blood       Date:  2003-10-30       Impact factor: 22.113

Review 10.  Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis.

Authors:  Elmira Agah; Arshia Zardoui; Amene Saghazadeh; Mona Ahmadi; Abbas Tafakhori; Nima Rezaei
Journal:  PLoS One       Date:  2018-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.